Naturally occurring multipotent anti-Alzheimer's agents
Hong-Yu Zhang1, Da-Peng Yang, Hong-Fang Ji
1Shandong Provincial Research Center for Bioinformatic Engineering and Technique, Center for Advanced Study, Shandong University of Technology, Zibo 255049, PR China. zhanghy@sdut.edu.cn.
Expert Opinion on Drug Discovery
|March 19, 2013
Summary
Multipotent natural compounds offer a promising strategy against Alzheimer's disease (AD), targeting multiple factors unlike single-target drugs. Research highlights these natural agents and their potential for developing more effective AD therapies.
Area of Science:
- Neuroscience
- Pharmacology
- Natural Product Chemistry
Background:
- Alzheimer's disease (AD) presents a significant medical challenge due to complex and not fully understood pathogenetic factors.
- Single-target therapeutic strategies have proven ineffective for AD, necessitating a shift towards multipotent agents.
- Naturally occurring compounds with multiple active components are highly attractive for AD drug development.
Purpose of the Study:
- To profile naturally derived multipotent compounds with potential anti-Alzheimer's disease (AD) activity.
- To summarize the structural features of these naturally occurring multipotent agents.
- To identify additional pleiotropic agents from natural product libraries based on structure-activity relationships for future AD therapeutic development.
Main Methods:
- Review and summarization of existing literature on naturally originated multipotent anti-AD compounds.
- Analysis of structural features and pharmacophores of identified natural compounds.
- Application of structure-activity relationship (SAR) studies to identify novel pleiotropic agents from natural product databases.
Main Results:
- A profile of naturally occurring multipotent compounds with demonstrated or potential anti-AD activity was described.
- Key structural characteristics contributing to the multipotent nature of these compounds were summarized.
- Several promising pleiotropic agents were identified from natural product libraries, warranting further investigation.
Conclusions:
- Multipotent natural compounds represent a viable and attractive alternative to single-target approaches for Alzheimer's disease treatment.
- Understanding the structure-activity relationships of these natural agents is crucial for optimizing their therapeutic potential.
- Further development of these naturally derived multipotent compounds holds significant promise for future Alzheimer's disease therapies.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
02:30siRNA - Small Interfering RNAs
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...